Biology and therapeutic targeting of vascular endothelial growth factor A.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic overview without systematic trial aggregation
PubMed 37491579 · doi:10.1038/s41580-023-00631-w
What was done
This is a narrative review summarizing literature on the molecular, structural, and cellular basis of vascular endothelial growth factor A (VEGFA) signaling via VEGFR1 and VEGFR2, along with its therapeutic targeting in oncology, ophthalmology, and regenerative medicine.
What was found
The abstract provides no primary quantitative data or statistical effect sizes. It states that all current FDA-approved anti-angiogenic agents target the VEGF pathway, functioning as standard-of-care treatments for multiple malignancies and neovascular eye disorders, such as age-related macular degeneration and ischaemic retinal diseases.
Why it matters
VEGFA represents the primary validated clinical target for pathological angiogenesis across cancer and retinal disorders, with expanding research into novel pathway interactions and tissue regeneration.
Limits
As a narrative review, it lacks a systematic literature search, quantitative pooling, or bias appraisal. The abstract provides no primary clinical data, patient sample sizes, or outcome metrics.
Cited by
- supports Vascular endothelial growth factor (VEGF) is a growth factor that stimulates angiogenesis and blood vessel formation in tissue.